Dyno Therapeutics and Trisk Bio Forge Strategic Manufacturing Alliance to Advance Genetic Agency through Expanded Frontiers Program
Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to revolutionize in vivo gene delivery, has announced a landmark manufacturing partnership with Trisk Bio Ltd., a specialist adeno-associated virus (AAV) manufacturing organization. The announcement was made during Dyno’s Genetic Agency Technology Conference (GATC) held in Boston. Through this alliance, Trisk Bio becomes the first official Frontiers Manufacturing Partner under Dyno’s expanded Frontiers Program, marking a major step toward building an integrated developer-manufacturer ecosystem that streamlines gene therapy innovation from design to production.
The collaboration reflects Dyno’s mission to unlock the full potential of gene therapies by applying AI to engineer next-generation AAV capsids optimized for therapeutic efficacy, manufacturability, and scalability. With Trisk Bio’s advanced bioprocessing capabilities now embedded within the program, the partnership establishes a direct bridge between cutting-edge capsid innovation and industrial-scale production, reducing risk, cost, and timelines for therapeutic developers worldwide.
Building the Frontiers Ecosystem
The Dyno Frontiers Program, first unveiled in May 2025, was conceived to empower gene therapy developers by providing access to Dyno’s proprietary AI-driven capsid libraries and non-human primate (NHP) study expertise. These capabilities allow researchers to evaluate therapeutic vectors more efficiently and to accelerate the translation of promising preclinical findings into clinical readiness.
The newly expanded program now adds a dedicated manufacturing marketplace, offering developers immediate access to qualified AAV producers like Trisk Bio who are already equipped with Dyno’s technology. This extension is designed to eliminate technical barriers that have historically slowed therapeutic progress—such as inefficient capsid production, low yield, or high cost—thus enabling faster and more predictable transitions from discovery to human trials.
By integrating AI-based capsid discovery with manufacturing partners specialized in AAV production, Dyno is redefining how the gene therapy pipeline operates—turning what was once a fragmented process into a coordinated ecosystem that fosters collaboration, efficiency, and innovation.
Trisk Bio: Pioneering AAV Manufacturing Excellence
Trisk Bio brings extensive expertise in intensified, fully scalable, and high-purity AAV production to the collaboration. The company has invested heavily in refining and validating manufacturing processes tailored specifically to Dyno’s engineered capsids. These optimized workflows ensure consistent high-quality yields while maintaining flexibility for scale-up and cost-efficiency—two critical factors for developers seeking to transition from lab-scale proof-of-concept to large-scale manufacturing.
“As we expand the Dyno Frontiers Program, we’re building the first initiative that connects developers, technology innovators, Therapeutics and manufacturers in a unified framework,” said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno Therapeutics. “By integrating manufacturing partners like Trisk, we’re reducing execution risks, shortening development timelines, and enabling our partners to deliver novel gene therapies more efficiently. This ecosystem reflects our core vision of genetic agency—a future where every patient has the ability to take genetic action to improve their health.”
Kelsic emphasized that broad collaboration and healthy competition among ecosystem partners are essential for making gene therapy development more accessible and sustainable, particularly for smaller biotechnology companies targeting rare or underserved diseases.
Delivering Value to Gene Therapy Developers
For therapeutic developers, the enhanced Frontiers Program delivers immediate and practical benefits. Companies can now access pre-validated manufacturers already familiar with Dyno’s capsid systems, dramatically reducing uncertainty in early development. This alignment accelerates readiness for non-human primate studies—often one of the most time-consuming stages of preclinical work—and provides a streamlined path to clinical-grade material production.
“When we were selecting a delivery platform for our epilepsy program, Dyno stood out as the ideal partner due to their AI-driven AAV capsid expertise and commitment to optimizing gene delivery,” said Boaz Levi, Co-founder and CEO of EpiCure Therapeutics, a company participating in Dyno’s Frontiers Program. “We also recognized that scalable and reliable manufacturing support is equally crucial. The integration of manufacturing partners like Therapeutics Trisk gives developers like us greater confidence and speed as we move life-changing therapies toward patients.”
This alignment between innovation and production not only reduces technical risks but also enhances flexibility for developers working across different therapeutic areas, including neurological, muscular, and metabolic disorders.
Trisk Bio’s Perspective: From Process to Partnership
Trisk Bio’s collaboration with Dyno extends beyond simple process implementation—it represents a strategic investment in the future of gene therapy manufacturing. The company has spent over a year developing robust, fully scalable production pipelines for multiple Dyno capsids, including purification methods that rely solely on chromatography.
“We’ve been deeply impressed by Dyno’s scientific Therapeutics rigor and forward-thinking approach,” said Gaurav Venkataraman, CEO of Trisk Bio. “Their commitment to building a sustainable, end-to-end ecosystem ensures that partners like us can provide reliable manufacturing routes from research-grade material to clinical and commercial supply. We see this as a long-term collaboration that sets a new standard for efficiency and quality in AAV manufacturing.”
Through its partnership with Dyno, Trisk aims to expand its manufacturing portfolio and work alongside a diverse range of gene therapy developers using Dyno’s engineered capsids. This collaboration also allows Trisk to stay at the forefront of evolving manufacturing challenges—such as scalability, regulatory readiness, and cost optimization—by integrating early-stage R&D insights directly into production design.
Advancing Genetic Agency and Accessibility
Central to Dyno’s mission is the concept of genetic agency—the ability for individuals to influence their health outcomes by accessing safe, effective, and affordable Therapeutics genetic medicines. The partnership with Trisk Bio is a major enabler of this vision. By connecting advanced capsid engineering with reliable manufacturing infrastructure, Dyno aims to democratize gene therapy development, making it more practical and economically viable even for rare and ultra-rare diseases that have historically lacked investment.
The expanded Frontiers Program not only serves leading biotech firms but also encourages smaller developers, contract research organizations (CROs), and startups to participate in a shared innovation network. By pooling expertise, resources, and infrastructure, Dyno and its partners hope to lower entry barriers and create a sustainable model for the next generation of genetic medicine.
Expanding the Network: A Call to Partners
Following the addition of Trisk Bio as the inaugural Frontiers Therapeutics Manufacturing Partner, Dyno is actively seeking to broaden its manufacturing network. The company is inviting additional Contract Development and Manufacturing Organizations (CDMOs), CROs, and academic or industry partners interested in integrating with Dyno’s AI-powered capsid platform.
This multi-partner ecosystem will allow developers to select from a range of qualified manufacturing options, promoting flexibility, competition, and scalability across different therapeutic modalities and target tissues. The goal is to create a thriving network that brings gene therapy from concept to clinic faster than ever before.
Organizations interested in becoming Frontiers Manufacturing Partners can reach Dyno at partnerwith@dynotx.com, while gene therapy developers can explore participation opportunities and learn more about Dyno’s Therapeutics technology at dynotx.com/frontiers-program.
A Step Toward the Future of Gene Therapy
The strategic partnership between Dyno Therapeutics and Trisk Bio underscores a fundamental evolution in the biotechnology industry—from isolated innovation to integrated ecosystems. As AI continues to accelerate capsid discovery and optimization, partnerships like this ensure that technological breakthroughs are matched by scalable manufacturing pathways, making real-world therapeutic impact achievable.
Through this collaboration, Dyno Therapeutics continues to position itself not just as a technology provider, but as a catalyst for systemic change in the gene therapy landscape. By merging computational biology, advanced manufacturing, and collaborative innovation, the company is building the foundation for a future where genetic agency is not a privilege, but a global standard.
About Dyno Therapeutics, Inc.
Dyno Therapeutics applies artificial intelligence to solve the challenges of in vivo gene delivery. Its proprietary AI platform enables the design of optimized AAV capsids with superior performance, supporting the development of safe and effective genetic medicines.
About Trisk Bio Ltd.
Trisk Bio is an AAV manufacturing specialist offering fully scalable, Therapeutics chromatography-based purification and production systems for next-generation gene therapy candidates. The company partners with innovators worldwide to deliver reliable, cost-effective, and high-purity vector manufacturing solutions.
Source Link: https://www.businesswire.com/
